JPRN-jRCT2080220098
Unknown
Phase 3
Double-blind confirmatory study of AD-5423 (blonanserin) in patients with schizophrenia [Phase 3 study]
Overview
- Phase
- Phase 3
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 15age old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- •\[Major inclusion criteria]
- •1\) Patients with schizophrenia who are classified as F.20 in the ICD 10 Diagnostic Criteria for Research (DCR 10\)
- •2\) Patients aged 15 years or older
- •3\) Either male or female
- •4\) Either inpatients or outpatients
- •5\) Patients who have given written informed consent
- •\[Major exclusion criteria]
- •1\) Patients with excitation/stupor as a primary clinical feature at initiation of the study.
- •2\) Patients with deteriorating or intractable schizophrenia.
- •3\) Patients for whom evaluation of adverse drug reactions (ADRs) cannot be performed.
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Unknown
Phase 3
A double-blind confirmatory study for AD-810N (zonisamide) in patients with Parkinson's disease (Phase III)Parkinson's diseaseJPRN-jRCT2080221162Dainippon Sumitomo Pharma Co., Ltd.360
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of AD-224Hypertension,EssentialNCT06291207Addpharma Inc.252
Completed
Phase 3
Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking ImpairmentWalking ImpairmentMultiple SclerosisNCT03436199Adamas Pharmaceuticals, Inc.558
Not yet recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282Primary HypercholesterolemiaNCT06747936Addpharma Inc.110
Completed
Not Applicable
A clinical study to assess the efficacy of a probiotic supplement for women to reduce depression and anxiety symptoms after giving birthImprovement of post-partum depression and mastitis in healthy new mothers and reduction of excessive crying in the newborns.Mental and Behavioural DisordersISRCTN99047904Roelmi HPC200